Genstruct, Inc. Appoints Michael R. Pavia to Board of Directors

Strategic Insights

Mar 20, 2005 — 1 min read

Genstruct, a systems biology company, has added a prominent figure to its board of directors. Michael R. Pavia, a highly experienced executive in the pharmaceutical industry, has joined the company's board with a strong track record in developing and integrating new technologies into the drug-discovery and -development process. Pavia's expertise is expected to play a crucial role in growing Genstruct's relationships with major pharmaceutical companies, such as Pfizer and Berlex, leveraging his past experience as the CTO of Millennium Pharmaceuticals. As an entrepreneur-in-residence with Oxford Biosciences Partners, Pavia brings valuable insights to Genstruct, which is focused on complex diseases in oncology, metabolic disorders, and inflammation.

Key Takeaways:

Michael R. Pavia, former CTO of Millennium Pharmaceuticals, has been appointed to Genstruct's board of directors, bringing over 20 years of pharmaceutical research and discovery experience.
Pavia's expertise in integrating new technologies into drug-discovery and -development processes is expected to grow Genstruct's relationships with pharmaceutical companies like Pfizer and Berlex.
As an entrepreneur-in-residence with Oxford Biosciences Partners, Pavia will contribute to Genstruct's growth using his expertise in bringing new technology to pharmaceutical companies.
Genstruct is a systems biology company focused on understanding and treating complex diseases in oncology, metabolic disorders, and inflammation.
The company, founded in 2002, aims to leverage new approaches to tackle these complex diseases.

Statistics:

20 years of experience in pharmaceutical research and discovery for Michael R. Pavia.
Genstruct was founded in 2002.
The company is focused on complex diseases in oncology, metabolic disorders, and inflammation.

Sources:

Health & Medicine Week
NewsRx.com
Oxford Biosciences Partners
Millennium Pharmaceuticals was founded, although no date is mentioned in the article, according to company history.

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients